IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice

Clinical and Experimental Immunology

Volumn 108, Issue 2, 1997, Pages 314-317

  Sandberg, J O ^a,b   Eizirik, D L ^a   Sandler, S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

cytokine; IL 1 receptor antagonist; insulin dependent diabetes mellitus; non obese diabetic mouse; pancreatic islet transplantation

Indexed keywords

IMMUNOMODULATING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOMODULATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSMOTIC PUMP; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030920680     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.3771275.x     Document Type: Article

References (25)

1. Gores PP, Najarian JS, Stephanian E, Lloveras JJ, Kelley SL, Sutherland DER. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341:19-21.
2. Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 1986; 35:1302-4.
3. Wang Y, Halo L, Gill RG, Lafferty KJ. Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 1987; 36:535-8.
4. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin-1. Proc Natl Acad Sci USA 1990; 87:968-72.
5. Rabinovitch A. Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev 1993; 1:215-40.
6. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power FP. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted non-obese diabetic mice. J Immunol 1995; 154:4874-82.
7. Sandberg J-O, Eizirik DL, Sandler S, Tracey DE, Andersson A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 1993; 42:1845-51.
8. Sandberg J-O, Andersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994; 202:543-8.
9. Mellgren A, Schnell-Landström A, Petersson B, Andersson A. The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islets than the liver or the spleen. Diabetologia 1986; 29:670-2.
10. Sandler S, Andersson A, Hellerström C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 1987; 121:1424-31.
11. Eizirik DL, Tracey DE, Bendtzen K, Sandler S. Role of receptor binding and gene transcription for both the stimulatory and inhibitory effects of interleukin-1 in pancreatic β-cells. Autoimmunity 1992; 12:127-33.
12. Eizirik DL, Tracey DE, Bendtzen K, Sandler S. An interleukin-1 receptor antagonist protein protects insulin-producing β-cells against suppressive effects of interleukin-1. Diabetologia 1991; 34:445-8.
13. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: applications for therapeutic intervention in human disease. Immunol Today 1994; 15:115-20.
14. Sandler S, Eizirik DL, Svensson C, Strandell E, Welsh M, Welsh N. Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 1991; 10:241-53.
15. Bendtzen K. Immune hormones (cytokines): pathogeneic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 1989; 2:177-89.
16. Nicoletti N, Di Marco R, Barcellini W et al. Protection from experimental autoimmune diabetes in the non-obese mouse with soluble interleukin-1 receptor. Eur J Immunol 1994; 24:1843-7.
17. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
18. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Letters 1994; 43:111-23.
19. Debets R, Savelkoul HFJ. Cytokine antagonists and their potential therapeutic use. Immunol Today 1994; 15:455-8.
20. Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Mørch L, Helqvist S, Dinarello CA, Nerup J. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993; 5:185-91.
21. McCarthy Jr PL, Abhyankar S, Neben S, Newman G, Sieff C, Burakoff SJ, Ferrara JLM. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78:1915-8.
22. Welsh M, Welsh N, Bendtzen K, Mares J, Strandell E, Öberg C, Sandler S. Comparison of mRNA contents of interleukin-1β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice. Diabetologia 1995; 38:153-60.
23. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerström C, Andersson A. Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury. Proc Natl Acad Sci USA 1994; 91:9253-6.
24. Eizirik DL, Sandler S, Palmer JP. Repair of pancreatic β-cells. A relevant phenomenon in early IDDM? Diabetes 1993; 43:1383-91.
25. Granowitz EV, Porat R, Mier JW et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353-60.